Haoyang Shi Selected Research

Immunotherapy

1/2021

A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Haoyang Shi Research Topics

Disease

2	Neoplasms (Cancer) 09/2022 - 01/2021
1	Peroneal Neuropathies 07/2023
1	Diabetes Mellitus 05/2023
1	Obesity 05/2023
1	Neoplasm Metastasis (Metastasis) 09/2022

Drug/Important Bio-Agent (IBA)

1	SteroidsIBA 05/2023
1	LipidsIBA 09/2022
1	Glucose (Dextrose)FDA LinkGeneric 09/2022
1	Plant ExtractsIBA 09/2022
1	Amino Acids FDA Link 09/2022
1	Proteins (Proteins, Gene)FDA Link 01/2021

Therapy/Procedure

1	Decompression 07/2023
1	Operative Time 05/2023
1	Chinese Traditional Medicine (Traditional Chinese Medicine) 09/2022
1	Therapeutics 09/2022
1	Immunotherapy 01/2021